Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/9782
Citations
Scopus Web of ScienceĀ® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMoghaddami, M.-
dc.contributor.authorCohen, P.-
dc.contributor.authorStapleton, A.-
dc.contributor.authorBrown, M.-
dc.date.issued2001-
dc.identifier.citationUrology, 2001; 57(3):573-578-
dc.identifier.issn0090-4295-
dc.identifier.issn1527-9995-
dc.identifier.urihttp://hdl.handle.net/2440/9782-
dc.description.abstract<h4>Objectives</h4>The CD40 antigen is expressed by antigen-presenting cells, many kinds of epithelium, and carcinomas. As signaling through CD40 modulates the differentiation state of CD40-expressing cells, we wanted to investigate whether benign or malignant prostate epithelium expressed CD40.<h4>Methods</h4>Twenty-two paraffin-embedded and 10 snap-frozen human prostate tissue samples were analyzed by immunohistologic methods, using the basal cell-specific markers, high molecular weight cytokeratin (HMWCK) and keratin-14 (K14), and the luminal cell marker, low molecular weight cytokeratin (LMWCK), together with CD40. Fresh prostate tissue was cultured in vitro and analyzed by immunocytofluorescence.<h4>Results</h4>The pattern of CD40 expression was continuous on basal epithelial cells of normal and hyperplastic prostate glands but discontinuous in glands that featured prostatic intraepithelial neoplasia. Coexpression of CD40 with the basal cell-specific cytokeratins, HMWCK and K14, was confirmed by double labeling. In contrast, glandular epithelial cells in prostate adenocarcinoma did not express CD40 or these cytokeratins. A luminal cell phenotype defined as CAM5.2-positive and HMWCK-negative K14-negative was identified among primary epithelial cells cultured in vitro. Most of the cultured cells (more than 99%) were also CD40-negative.<h4>Conclusions</h4>Together, our results support the hypothesis that CD40 expression correlates with the basal cell phenotype, which is lost upon malignant transformation of the prostate. Hence, CD40 may be useful diagnostically to distinguish benign from malignant prostate lesions in biopsy material.-
dc.language.isoen-
dc.publisherElsevier Science Inc-
dc.source.urihttp://dx.doi.org/10.1016/s0090-4295(00)01005-0-
dc.subjectHumans-
dc.subjectAdenocarcinoma-
dc.subjectProstatic Intraepithelial Neoplasia-
dc.subjectProstatic Neoplasms-
dc.subjectProstatic Hyperplasia-
dc.subjectImmunohistochemistry-
dc.subjectMale-
dc.subjectKeratins-
dc.subjectBiomarkers, Tumor-
dc.subjectCD40 Antigens-
dc.titleCD40 is not detected on human prostate cancer cells by immunohistologic techniques-
dc.typeJournal article-
dc.identifier.doi10.1016/S0090-4295(00)01005-0-
pubs.publication-statusPublished-
dc.identifier.orcidBrown, M. [0000-0002-5796-1932] [0000-0002-6678-1407]-
Appears in Collections:Aurora harvest
Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.